GT200600159A - Derivados benzodioxano y benzodioxolano y usos de los mismos - Google Patents
Derivados benzodioxano y benzodioxolano y usos de los mismosInfo
- Publication number
- GT200600159A GT200600159A GT200600159A GT200600159A GT200600159A GT 200600159 A GT200600159 A GT 200600159A GT 200600159 A GT200600159 A GT 200600159A GT 200600159 A GT200600159 A GT 200600159A GT 200600159 A GT200600159 A GT 200600159A
- Authority
- GT
- Guatemala
- Prior art keywords
- benzodioxolan
- benzodioxan
- derivatives
- same
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
SE PROVEEN COMPUESTOS DE FÓRMULA I O SALES FARMACÉUTICAMENTE ACEPTABLES DE ESTOS, DONDE CADA UNO DE R1, R2, R3, R3, Y , N, M Y AR SON TAL COMO SE HAN DEFINIDO Y DESCRIPTO EN CLASES Y SUBCLASES AQUÍ, QUE SON AGONISTAS O AGONISTAS PARCIALES DEL SUBITPO 12 O LOS RECEPTORES CEREBRALES DE SEROTONINA. LOS COMPUESTOS, Y LAS COMPOSICIONES QUE CONTIENEN LOS COMPUESTOS, PUEDEN USARSE PARA TRATAR UNA VARIEDAD DE DESÓRDENES DEL SISTEMA NERVIOSO CENTRAL TAL COMO ESQUIZOFRENIA. T2006
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67388405P | 2005-04-22 | 2005-04-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200600159A true GT200600159A (es) | 2007-03-14 |
Family
ID=36688044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200600159A GT200600159A (es) | 2005-04-22 | 2006-04-21 | Derivados benzodioxano y benzodioxolano y usos de los mismos |
Country Status (20)
Country | Link |
---|---|
US (1) | US20060241172A1 (es) |
EP (1) | EP1871759A1 (es) |
JP (1) | JP2008538575A (es) |
KR (1) | KR20080009295A (es) |
CN (1) | CN101218223A (es) |
AR (1) | AR054035A1 (es) |
AU (1) | AU2006239930A1 (es) |
BR (1) | BRPI0610046A2 (es) |
CA (1) | CA2605580A1 (es) |
CR (1) | CR9459A (es) |
GT (1) | GT200600159A (es) |
IL (1) | IL186835A0 (es) |
MX (1) | MX2007013151A (es) |
NI (1) | NI200700270A (es) |
NO (1) | NO20075623L (es) |
PE (1) | PE20061335A1 (es) |
RU (1) | RU2007139543A (es) |
TW (1) | TW200720266A (es) |
WO (1) | WO2006116158A1 (es) |
ZA (1) | ZA200709043B (es) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
US7435837B2 (en) * | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
US20050261347A1 (en) * | 2003-10-24 | 2005-11-24 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
DK1530967T3 (da) * | 2003-11-13 | 2006-07-03 | Ferring Bv | Blisterpakning og dertil hörende fast dosisform |
TW200612905A (en) * | 2004-06-16 | 2006-05-01 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
CA2578407A1 (en) * | 2004-08-24 | 2006-03-02 | Janssen Pharmaceutica N.V. | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents |
GT200500297A (es) * | 2004-10-21 | 2006-10-27 | Sintesis asimetrica de dehidrobenzofuranos sustituidos | |
GT200500296A (es) * | 2004-10-21 | 2006-10-02 | Sintesis asimetrica de derivados del dehidrobenzofurano | |
BRPI0610036A2 (pt) * | 2005-04-22 | 2010-05-18 | Wyeth Corp | derivados de benzofuranil alcanamina e usos destes como agonìstico de 5-ht2c |
EP1871755A1 (en) * | 2005-04-22 | 2008-01-02 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
GT200600165A (es) * | 2005-04-22 | 2007-03-14 | Derivados dihidrobenzofuranos y usos de los mismos | |
PE20061318A1 (es) * | 2005-04-22 | 2006-12-28 | Wyeth Corp | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos |
EP1874756A1 (en) * | 2005-04-22 | 2008-01-09 | Wyeth | Chromane and chromene derivatives and uses thereof |
CA2605117A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Treatment of pain |
GT200600167A (es) * | 2005-04-22 | 2007-03-14 | Derivados de dihidrobenzofurano y usos de los mismos | |
BRPI0609952A2 (pt) * | 2005-04-24 | 2010-05-11 | Wyeth Corp | métodos para modular a função da bexiga |
EP1881959A1 (en) * | 2005-05-20 | 2008-01-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
US20070155827A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
US20070155823A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
US8497298B2 (en) * | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8716231B2 (en) * | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US8691867B2 (en) * | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US8937096B2 (en) * | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US8492431B2 (en) * | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
SE528446C2 (sv) * | 2006-03-02 | 2006-11-14 | Ferring Int Ct Sa | Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse |
CA2647048A1 (en) * | 2006-03-24 | 2007-10-04 | Wyeth | Methods for treating cognitive and other disorders |
AR060493A1 (es) * | 2006-04-18 | 2008-06-18 | Wyeth Corp | Derivados de benzodioxano y benzodioxolano. procesos de obtencion. |
EP2742936A1 (en) | 2006-05-16 | 2014-06-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
JP2009537635A (ja) * | 2006-05-19 | 2009-10-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 癲癇の処置のための共同−療法 |
CL2007003065A1 (es) * | 2006-10-24 | 2008-01-25 | Wyeth Corp | Compuestos derivados de benzodioxano, agonista 5ht2c, composicion farmaceutica que lois comprende; y sus uso en el tratamiento de un trastorno psicotico, ansiedad, depresion, trastorno bipolar, sindrome premenstrual, entre otros |
CL2007003044A1 (es) * | 2006-10-24 | 2008-07-04 | Wyeth Corp | Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros. |
US8399410B2 (en) | 2007-08-06 | 2013-03-19 | Allergan, Inc. | Methods and devices for desmopressin drug delivery |
EP2216023A4 (en) | 2007-11-15 | 2013-03-13 | Takeda Pharmaceutical | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF |
US20090247616A1 (en) * | 2008-03-26 | 2009-10-01 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety |
US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
AU2009242092A1 (en) | 2008-04-29 | 2009-11-05 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Modulators of dopamine neurotransmission |
EP2271635A1 (en) * | 2008-04-29 | 2011-01-12 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | Modulators of dopamine neurotransmission |
MX2010011498A (es) * | 2008-04-29 | 2010-11-12 | Nsab Af Neurosearch Sweden Ab | Moduladores de neurotransmision de dopamina. |
US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
LT3225249T (lt) | 2008-05-21 | 2019-01-10 | Ferring B.V. | Burnoje disperguojamas desmopresinas, skirtas pirminio miego periodo, nepertraukiamo nikturija, pailginimui |
BRPI0915890A2 (pt) * | 2008-06-23 | 2015-11-03 | Janssen Pharmaceutica Nv | forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida |
US8815939B2 (en) * | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
AR082286A1 (es) * | 2010-07-20 | 2012-11-28 | Bayer Cropscience Ag | Benzocicloalquenos como agentes antifungicos |
US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
BR112013015973B1 (pt) | 2010-12-21 | 2018-12-11 | Colgate-Palmolive Company | bifenóis halogenados como agentes antibacterianos. |
WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
CA3029109A1 (en) * | 2016-06-29 | 2018-01-04 | Orion Corporation | Benzodioxane derivatives and their pharmaceutical use |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
WO2019131902A1 (ja) | 2017-12-27 | 2019-07-04 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
GB201801128D0 (en) * | 2018-01-24 | 2018-03-07 | Univ Oxford Innovation Ltd | Compounds |
WO2020086864A1 (en) * | 2018-10-24 | 2020-04-30 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
CN109293480B (zh) * | 2018-10-31 | 2020-10-09 | 陕西硕博电子材料有限公司 | 二烯丙基双酚a、制备方法及双马来酰亚胺树脂预聚物 |
CN113993523A (zh) | 2019-04-17 | 2022-01-28 | 指南针探路者有限公司 | 用赛洛西宾治疗抑郁症和其他各种病症 |
JP2022545960A (ja) | 2019-08-26 | 2022-11-01 | ピリオド ピル ベーフェー | 月経周期性症状の治療 |
CA3179785A1 (en) * | 2020-06-08 | 2021-12-16 | Matthew BAGGOTT | Advantageous benzofuran compositions for mental disorders or enhancement |
CN112121463B (zh) * | 2020-09-15 | 2022-03-22 | 烟台宁远药业有限公司 | 一种多取代苯并含氮杂环甲胺的制备方法 |
CN114890978B (zh) * | 2022-04-19 | 2023-07-25 | 宿迁医美科技有限公司 | 酚类化合物及其制备方法和应用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2906757A (en) * | 1959-09-29 | Their preparation | ||
GB1054104A (es) * | 1962-07-20 | |||
US3872105A (en) * | 1973-06-11 | 1975-03-18 | Merrell Inc Richard | Derivatives of 1,3-benzodioxole-2-carboxylic acid |
US4118507A (en) * | 1977-03-17 | 1978-10-03 | Shell Oil Company | Benzodioxincarboxamide lipogenesis inhibitors |
US5120758A (en) * | 1991-02-08 | 1992-06-09 | Ciba-Geigy Corporation | Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors |
JP3454531B2 (ja) * | 1991-11-07 | 2003-10-06 | 三共株式会社 | ニトロキシアルキルアミド誘導体 |
US5731324A (en) * | 1993-07-22 | 1998-03-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
FR2716680B1 (fr) * | 1994-02-25 | 1996-04-05 | Adir | Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
JP3235448B2 (ja) * | 1995-03-24 | 2001-12-04 | ダイソー株式会社 | 1,4−ベンゾジオキサン誘導体の製法 |
US6514996B2 (en) * | 1995-05-19 | 2003-02-04 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of benzofuran or benzodioxole |
FR2791675B1 (fr) * | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique |
GB0007376D0 (en) * | 2000-03-28 | 2000-05-17 | Knoll Ag | Therapeutic agents |
NZ537685A (en) * | 2002-07-29 | 2007-06-29 | Hoffmann La Roche | Novel benzodioxoles |
US20050261347A1 (en) * | 2003-10-24 | 2005-11-24 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
US7728155B2 (en) * | 2003-10-24 | 2010-06-01 | Wyeth Llc | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents |
NZ550441A (en) * | 2004-05-05 | 2009-07-31 | Hoffmann La Roche | Arylsulfonyl benzodioxanes useful for modulating the 5-HT6 receptor, the 5-HT2A receptor or both |
GT200500296A (es) * | 2004-10-21 | 2006-10-02 | Sintesis asimetrica de derivados del dehidrobenzofurano | |
GT200500297A (es) * | 2004-10-21 | 2006-10-27 | Sintesis asimetrica de dehidrobenzofuranos sustituidos | |
EP1871755A1 (en) * | 2005-04-22 | 2008-01-02 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
GT200600165A (es) * | 2005-04-22 | 2007-03-14 | Derivados dihidrobenzofuranos y usos de los mismos | |
BRPI0610036A2 (pt) * | 2005-04-22 | 2010-05-18 | Wyeth Corp | derivados de benzofuranil alcanamina e usos destes como agonìstico de 5-ht2c |
PE20061318A1 (es) * | 2005-04-22 | 2006-12-28 | Wyeth Corp | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos |
GT200600167A (es) * | 2005-04-22 | 2007-03-14 | Derivados de dihidrobenzofurano y usos de los mismos | |
GT200600158A (es) * | 2005-04-22 | 2006-11-28 | Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina | |
CA2605117A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Treatment of pain |
BRPI0610044A2 (pt) * | 2005-04-22 | 2010-05-25 | Wyeth Corp | combinações terapêuticas para o tratamento ou prevenção de depressão |
EP1874756A1 (en) * | 2005-04-22 | 2008-01-09 | Wyeth | Chromane and chromene derivatives and uses thereof |
JP2008538766A (ja) * | 2005-04-22 | 2008-11-06 | ワイス | 薬物乱用の処置 |
BRPI0609952A2 (pt) * | 2005-04-24 | 2010-05-11 | Wyeth Corp | métodos para modular a função da bexiga |
-
2006
- 2006-04-21 AU AU2006239930A patent/AU2006239930A1/en not_active Abandoned
- 2006-04-21 WO PCT/US2006/015201 patent/WO2006116158A1/en active Application Filing
- 2006-04-21 CN CNA2006800226232A patent/CN101218223A/zh active Pending
- 2006-04-21 RU RU2007139543/04A patent/RU2007139543A/ru unknown
- 2006-04-21 AR ARP060101589A patent/AR054035A1/es unknown
- 2006-04-21 TW TW095114316A patent/TW200720266A/zh unknown
- 2006-04-21 MX MX2007013151A patent/MX2007013151A/es unknown
- 2006-04-21 BR BRPI0610046-5A patent/BRPI0610046A2/pt not_active Application Discontinuation
- 2006-04-21 US US11/409,466 patent/US20060241172A1/en not_active Abandoned
- 2006-04-21 EP EP06758485A patent/EP1871759A1/en not_active Withdrawn
- 2006-04-21 KR KR1020077027248A patent/KR20080009295A/ko not_active Application Discontinuation
- 2006-04-21 PE PE2006000414A patent/PE20061335A1/es not_active Application Discontinuation
- 2006-04-21 GT GT200600159A patent/GT200600159A/es unknown
- 2006-04-21 JP JP2008507951A patent/JP2008538575A/ja active Pending
- 2006-04-21 CA CA002605580A patent/CA2605580A1/en not_active Abandoned
-
2007
- 2007-10-19 NI NI200700270A patent/NI200700270A/es unknown
- 2007-10-19 ZA ZA200709043A patent/ZA200709043B/xx unknown
- 2007-10-19 CR CR9459A patent/CR9459A/es not_active Application Discontinuation
- 2007-10-22 IL IL186835A patent/IL186835A0/en unknown
- 2007-11-06 NO NO20075623A patent/NO20075623L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BRPI0610046A2 (pt) | 2010-05-25 |
TW200720266A (en) | 2007-06-01 |
NO20075623L (no) | 2008-01-17 |
CR9459A (es) | 2008-02-20 |
CA2605580A1 (en) | 2006-11-02 |
RU2007139543A (ru) | 2009-05-27 |
MX2007013151A (es) | 2008-01-16 |
AR054035A1 (es) | 2007-05-30 |
WO2006116158A1 (en) | 2006-11-02 |
IL186835A0 (en) | 2008-02-09 |
NI200700270A (es) | 2008-06-25 |
KR20080009295A (ko) | 2008-01-28 |
US20060241172A1 (en) | 2006-10-26 |
AU2006239930A1 (en) | 2006-11-02 |
ZA200709043B (en) | 2009-09-30 |
PE20061335A1 (es) | 2006-12-29 |
EP1871759A1 (en) | 2008-01-02 |
CN101218223A (zh) | 2008-07-09 |
JP2008538575A (ja) | 2008-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200600159A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
CO6321153A2 (es) | Derivados de cromeno y cromano y sus usos | |
UY28876A1 (es) | Compuestos de morfolina sustituida y composiciones para el tratamiento de trastornos del sistema nervioso central | |
ECSP066391A (es) | [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
ECSP055676A (es) | Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia | |
GT200600165A (es) | Derivados dihidrobenzofuranos y usos de los mismos | |
GT200600518A (es) | Derivados de pirimidina | |
ECSP066520A (es) | Derivados de dihidrobenzofuranilo alcanamina y métodos para su uso | |
GT200600167A (es) | Derivados de dihidrobenzofurano y usos de los mismos | |
AR058807A1 (es) | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 | |
AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
UY28150A1 (es) | Agentes terapeuticos | |
ECSP099728A (es) | Compuestos amino-heterocíclicos | |
AR056860A1 (es) | Derivados de triazol inhibidores de receptores de quinasa tgf-beta1, composiciones farmaceuticas que los contienen y usos para el tratamiento de tumores | |
CR10062A (es) | Composiciones y metodos de tratamiento para trastornos del sistema nervioso central | |
BRPI0924617A8 (pt) | Compostos heterociclicos de fenoximetila | |
AR061637A1 (es) | Composiciones y metodos de tratamiento de trastornos del snc | |
CR9407A (es) | Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
CR7735A (es) | Piperizinas heterociclicas sustituidas para el tratamiento de la esquizofrenia | |
UY27998A1 (es) | Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia | |
CL2008001559A1 (es) | Compuestos heterociclos que contienen al menos un atomo de nitrogeno, moduladores de gamma secretasa; composiciones farmaceuticas que los comprenden; uso de los compuestos en la preparacion de medicamentos para tratar trastornos del sistema nervioso central, tal como alzheimer; y kit que incluye a la composicion farmaceutica. | |
UY28656A1 (es) | Derivados de indano heterocíclicos sustituidos y compuestos relacionados para el tratamiento de esquizofrenia | |
UY29052A1 (es) | Nuevos inhibidores de la recaptación de norepinefrina de quinoxalinona para el tratamiento de trastornos del sistema nervioso central | |
DOP2003000709A (es) | Piperazinas heterociclicas sustituidas para el tratamiento de la esquizofrenia | |
DOP2005000068A (es) | Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central |